Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ezetimibe Extension in Homozygous Sitosterolemia
NCT00092820Phase 3Completed
- Sponsor
- Organon & Co.
- Start
- Feb 2001
- Primary completion
- Sep 2001
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in sitosterolemia comparing MK0653 + Current Regimen with Placebo + Current Regimen (2 arms). Primary endpoint: Plasma sitosterol levels at 52 weeks. Started Feb 2001; status: completed.
02
Drugs
ezetimibe
03
Conditions
sitosterolemia
Beyond the preview
Go deeper on NCT00092820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00092820.